The Current State of Targeted Agents in Rectal Cancer

Table 3

Clinical trials of bevacizumab in preoperative treatment of rectal cancer.

Author	Phase	Study design(regimen)	𝑁	RT dose (Gy)	pCR rate	Major wound Cx	Reference
Machiels	I	Cape + oxali + bevacizumab	11	50.4	2/11(18%)	NS	[45]
Willett	II	5FU + bevacizumab	32	50.4	5/32(16%)	1/32(3%)	[29]
Rodel	II	5FU + bevacizumab	35	50.4	10/35(29%)	3/20(15%)	[46]
Crane	II	Capecitabine + bevacizumab	25	50.4	8/25(32%)	3/25(12%)	[47]
Mourad	II	Xelox + beva then cape + beva + RT	47	50.4	16/47(36%)	11/47(24%)	[48]

RT: Radiotherapy, pCR: Pathological complete response.